Tallulah Holmstrom, MD
Internal Medicine · Lugoff, SCNPI 1053363887
Payments from drug & device makers
Across 173 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$314
- Novo Nordisk$261
- Amgen$242
- Teva Pharmaceuticals USA, Inc.$239
- AstraZeneca$235
- Boehringer Ingelheim$225
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,77296%
- Education$1164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $314 |
| Novo Nordisk | 12 | $261 |
| Amgen | 16 | $242 |
| Teva Pharmaceuticals USA, Inc. | 10 | $239 |
| AstraZeneca | 14 | $235 |
| Boehringer Ingelheim | 10 | $225 |
| Johnson & Johnson | 7 | $170 |
| AbbVie | 15 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $137 |
| Amarin Pharma, Inc. | 9 | $130 |
| Astellas Pharma US Inc | 7 | $94 |
| Pfizer | 5 | $63 |
| Eisai Inc. | 4 | $56 |
| Novartis | 3 | $51 |
| Arbor Pharmaceuticals, Inc. | 2 | $44 |
| Sanofi Pasteur Inc. | 3 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Lilly USA, LLC | 3 | $38 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Zyla Life Sciences, Inc. | 2 | $33 |
| Optinose US, Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Insmed, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Shionogi Inc | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Pulmonx Corporation | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Abbott | 1 | $12 |
| Merck | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Clarus Therapeutics Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$127
- JARDIANCE$102
- Ozempic$102
How this compares
$2,888 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $54,335 |
| EliquisApixaban | 71 | $51,206 |
| RybelsusSemaglutide | 28 | $39,913 |
| MounjaroTirzepatide | 28 | $32,754 |
| JardianceEmpagliflozin | 24 | $27,052 |
| Repatha SureclickEvolocumab | 14 | $20,099 |
| MyrbetriqMirabegron | 27 | $19,192 |
| XareltoRivaroxaban | 14 | $11,510 |
| LinzessLinaclotide | 16 | $10,342 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,065 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $6,094 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $5,266 |
| Levothyroxine Sodium | 375 | $4,635 |
| Rosuvastatin Calcium | 269 | $4,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $261 | $94,24973 claims |
| PfizerEliquis | $63 | $51,20671 claims |
| Lilly USA, LLCMounjaro | $38 | $32,75428 claims |
| Boehringer IngelheimJardiance | $225 | $27,05224 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $19,19227 claims |
| AbbVieLinzess, Synthroid | $162 | $12,79868 claims |
| Johnson & JohnsonXarelto | $170 | $11,51014 claims |
| GSKTrelegy Ellipta | $314 | $8,06511 claims |
| MerckJanumet Xr | $12 | $6,09411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Lugoff
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.